Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CASP1 | P29466 | 7/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409148 | 1.00 | ALDH1A1 (0.35) | ALDH1A1CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL1409882 | 0.82 | ADRB2 (0.48) | ALDH1A1CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL646188 | 0.79 | CASP1 (0.44) | CASP1CASP3 | |
| SCHEMBL311041 | 0.78 | KLK5 (0.36) | ALDH1A1CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL7254765 | 0.78 | CASP3 (0.38) | ALDH1A1CASP1CASP3TXNRD1HPGD | |
| SCHEMBL1409757 | 0.77 | ALDH1A1 (0.34) | ALDH1A1CASP1MAPT | |
| SCHEMBL2217366 | 0.76 | LMNA (0.33) | ALDH1A1CASP1ADRB2ADRB1ADRB3 | |
| SCHEMBL8764759 | 0.72 | CASP1 (0.47) | CASP1CASP3TXNRD1 | |
| SCHEMBL6405747 | 0.71 | CASP1 (0.37) | ALDH1A1CASP1CASP3HPGDMEN1 | |
| SCHEMBL4439353 | 0.71 | CYP3A4 (0.58) | ALDH1A1TXNRD1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | ALDH1A1 422/4885CASP1 6/4885ADRB2 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.